New diabetes drug IBI362 takes on semaglutide in Head-to-Head weight loss and blood sugar battle
NCT ID NCT06184568
First seen Nov 17, 2025 · Last updated May 24, 2026 · Updated 24 times
Summary
This study tests a new weekly injection called IBI362 against the existing drug semaglutide in 349 Chinese adults with early type 2 diabetes and obesity. The goal is to see if IBI362 is better at lowering blood sugar and helping people lose weight. Participants will receive either drug for 32 weeks, and some may continue IBI362 for another 24 weeks to see if weight loss goals are met.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100010, China
Conditions
Explore the condition pages connected to this study.